In conclusion, the possibility to reduce ENaC activity using drugs already approved as therapeutics for other pathologies or a non-toxic dietary compound, with no repression or even enhancement of CFTR expression, open new possibilities for CF treatment. The gene discussed is CFTR; the disease is cystic fibrosis.